Vertex beats, raises
Vertex posted a slight revenue beat and raised full-year sales guidance, while adjusted EPS came in a bit light as Crinetics deal costs and launch spending rose, and the stock moved moderately higher.
Sources: https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm, https://www.investing.com/news/earnings/4992435, https://finance
Previous verdicts for VRTX
- Vertex outlook lifts — 2026-11-04
- AI Search: Vertex Rallies as FDA Approvals Expand Cystic Fibrosis Labels — 2026-10-30
- AI Search: Vertex Rises Modestly as Povetacicept Phase 3 Data Published — 2026-10-29
- AI Search: BofA trims Vertex target; VRTX edges higher on technical bounce — 2026-10-22
- AI Search: Vertex Pharmaceuticals Rises Modestly on Pipeline Coverage and Board News — 2026-10-21
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works